Basis: FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/S ratio is N/A as of 2026-10-06T16:33:07.646Z.
Calculation as of: 2026-10-06T16:33:07.646Z.
Quote observation: 2026-10-06T16:29:17.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: d2baa5019f568993ecceb1943c30cf17443c8d153a00c2cc4d930c3e59df60e4
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PS RATIO
N/A
Liminatus Pharma, Inc. Class A Common Stock
Market Cap
$5.23M
PS Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$5.20M
PS Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$5.29M
PS Ratio
1.26
TTM Avg
1.37
3Y Avg
1.98
5Y Avg
32.27
| NAME | MARKET CAP | PS RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Liminatus Pharma, Inc. Class A Common Stock (LIMN) | $5.23M | N/A | N/A | N/A | N/A |
| Gelteq Limited Ordinary Shares (GELS)vs › | $5.23M | N/A | N/A | N/A | N/A |
| Lunai Bioworks Inc. (LNAI)vs › | $5.21M | 248.97 | 372.81 | 372.81 | 372.81 |
| Basel Medical Group Ltd Ordinary Shares (BMGL)vs › | $5.20M | N/A | N/A | N/A | N/A |
| Alzamend Neuro Inc (ALZN)vs › | $5.29M | N/A | N/A | N/A | N/A |
| Intelligent Bio Solutions Inc. (INBS)vs › | $5.29M | 1.26 | 1.37 | 1.98 | 32.27 |
| Soligenix, Inc. (SNGX)vs › | $5.34M | N/A | 41.56 | 161.30 | 129.34 |
| Pulmatrix, Inc. (PULM)vs › | $5.41M | N/A | 1549.76 | 519.51 | 312.87 |
| Imunon, Inc. (IMNN)vs › | $5.02M | N/A | 52.54 | 81.05 | 85.82 |
| Acurx Pharmaceuticals, Inc. (ACXP)vs › | $5.59M | N/A | N/A | N/A | N/A |
Trailing-12-month revenue adds these four fiscal quarters. Amounts are in USD, rounded only to whole currency units.
| Fiscal period | Revenue | Source |
|---|---|---|
| Q3 FY2025Period ended 2025-09-30 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2025-11-14 |
| Q4 FY2025Period ended 2025-12-31 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-03-31 |
| Q1 FY2026Period ended 2026-03-31 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-05-15 |
| Q2 FY2026Period ended 2026-06-30 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-08-14 |
| TTM revenue | $0 |
The current P/S calculation cannot be reconciled from the stored quote and revenue inputs.
These references are supplied through FMP. Full filing context identifiers and dimensional metadata are unavailable in the normalized feed.
P/S Ratio
N/A
Market Cap / Trailing Twelve-Month Revenue
PS Ratio = Market Cap / Revenue (TTM)
The price-to-sales ratio compares market capitalization to trailing revenue. It is useful for valuing companies with little or no earnings.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
